Zigao Yuan
State Key Laboratory Of Chemical Oncogenomics
Shenzhen, 518055, China
Shenzhen, 518055, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity.
Journal: Journal of medicinal chemistry
Published: August 29, 2025
Targeting HDAC and PARP Enhances STING-Dependent Antitumor Immunity in STING-Deficient Tumor.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 01, 2025
Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy.
Journal: Pharmacological research
Published: April 25, 2024
Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer.
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: January 22, 2024
Dual inhibitors of DNMT and HDAC induce viral mimicry to induce antitumour immunity in breast cancer.
Journal: Cell death discovery
Published: January 12, 2024
Discovery of novel nucleoside derivatives as selective lysine acetyltransferase p300 inhibitors for cancer therapy.
Journal: Bioorganic & medicinal chemistry letters
Published: November 28, 2023
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer.
Journal: Cell death & disease
Published: July 08, 2023
Metabolic profiling on the effect of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) in MCF-7 cells.
Journal: Chemosphere
Published: August 19, 2017
PARP inhibitors as antitumor agents: a patent update (2013-2015).
Journal: Expert opinion on therapeutic patents
Published: November 15, 2016
Showing 1-9 of 9
Last Updated: 09/26/2026